These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26264203)

  • 1. Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review.
    Mahajan M; Khurana RK; Sahajpal NS; Utreja P; Sankar R; Singh B; Jain SK
    Curr Drug Metab; 2015; 16(6):453-73. PubMed ID: 26264203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macromolecules as taxane delivery systems.
    Dosio F; Stella B; Arpicco S; Cattel L
    Expert Opin Drug Deliv; 2011 Jan; 8(1):33-55. PubMed ID: 21142695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer.
    van Eerden RAG; Mathijssen RHJ; Koolen SLW
    Int J Nanomedicine; 2020; 15():8151-8166. PubMed ID: 33132699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer.
    Wang S; Qiu J; Shi Z; Wang Y; Chen M
    Biotechnol Adv; 2015; 33(1):224-241. PubMed ID: 25447422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of docetaxel and chloroquine via PEO-PPO-PCL/TPGS micelles for overcoming multidrug resistance.
    Shi C; Zhang Z; Shi J; Wang F; Luan Y
    Int J Pharm; 2015 Nov; 495(2):932-9. PubMed ID: 26456262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Larotaxel: broadening the road with new taxanes.
    Metzger-Filho O; Moulin C; de Azambuja E; Ahmad A
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1183-9. PubMed ID: 19604119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Sojourn from Parenteral to Oral Taxanes using Nanocarrier Systems: A Patent Review.
    Khurana RK; Mahajan M; Teenu ; Kapoor S; Jain S; Singh B
    Recent Pat Drug Deliv Formul; 2016; 10(1):44-58. PubMed ID: 26427603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The benefits and challenges associated with the use of drug delivery systems in cancer therapy.
    Cukierman E; Khan DR
    Biochem Pharmacol; 2010 Sep; 80(5):762-70. PubMed ID: 20417189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer.
    Kroon J; Kooijman S; Cho NJ; Storm G; van der Pluijm G
    Trends Pharmacol Sci; 2016 Jun; 37(6):451-462. PubMed ID: 27068431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Delivery Systems Based on Polymeric Micelles and Ultrasound: A Review.
    Tanbour R; Martins AM; Pitt WG; Husseini GA
    Curr Pharm Des; 2016; 22(19):2796-807. PubMed ID: 26898742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer.
    Malam Y; Loizidou M; Seifalian AM
    Trends Pharmacol Sci; 2009 Nov; 30(11):592-9. PubMed ID: 19837467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging nanotechnology based combination therapies of taxanes for multiple drug-resistant cancers.
    Katekar R; Singh P; Garg R; Verma S; Gayen JR
    Pharm Dev Technol; 2022 Jan; 27(1):95-107. PubMed ID: 34806547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The intravenous to oral switch of taxanes: strategies and current clinical developments.
    Vermunt MA; Bergman AM; der Putten EV; Beijnen JH
    Future Oncol; 2021 Apr; 17(11):1379-1399. PubMed ID: 33356545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticles for drug delivery in cancer treatment.
    Haley B; Frenkel E
    Urol Oncol; 2008; 26(1):57-64. PubMed ID: 18190833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tubulin: an example of targeted chemotherapy.
    Seligmann J; Twelves C
    Future Med Chem; 2013 Mar; 5(3):339-52. PubMed ID: 23464522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
    Beretta GL; Cavalieri F
    Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel taxanes in development: Hopes or hypes?
    Lei L; Wang XJ; Tang SC
    Crit Rev Oncol Hematol; 2022 Aug; 176():103727. PubMed ID: 35644326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics.
    Reddy LH; Bazile D
    Adv Drug Deliv Rev; 2014 May; 71():34-57. PubMed ID: 24184489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly-L-asparagine nanocapsules as anticancer drug delivery vehicles.
    Rivera-Rodríguez GR; Alonso MJ; Torres D
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):481-7. PubMed ID: 23954509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New taxanes in development.
    Ferlini C; Gallo D; Scambia G
    Expert Opin Investig Drugs; 2008 Mar; 17(3):335-47. PubMed ID: 18321233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.